1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

14 Jul 2025
Admin
News Article

US FDA approves Moderna’s Covid-19 vaccine, Spikevax in children aged 6 months through 11 years

Overview

Moderna, Inc., a leader in the creation of the field of mRNA medicine, announced that the US Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Spikevax, the company's Covid-19 vaccine, in children 6 months through 11 years of age who are at increased risk for Covid-19 disease. The company's Covid-19 vaccine, mRNA-1273, was previously available for paediatric populations under Emergency Use Authorization (EUA).

Statement from Stéphane Bancel: CEO, Moderna

""Covid-19 continues to pose a significant potential threat to children, especially those with underlying medical conditions. Vaccination can be an important tool for protecting our youngest against severe disease and hospitalization,"" said Stéphane Bancel, chief executive officer of Moderna. ""We appreciate the FDA's diligent scientific review and approval of Spikevax for paediatric populations at increased risk for Covid-19 disease.""

Moderna to Launch Updated Spikevax for 2025-2026 Season

Moderna expects to have its updated Spikevax vaccine available for eligible populations in the US for the 2025-2026 respiratory virus season.
Moderna- Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how it treat and prevent disease for everyone.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!